Aberrant intermediate alveolar epithelial cells promote pathogenic activation of lung fibroblasts in preclinical fibrosis models - Nature Communications The direct contribution of aberrant epithelial cells to lung fibrosis is largely unknown. The authors use murine and human systems to identify how these cells activate fibroblasts, and how reciprocal signals cause them to enter a profibrotic state.

Announcing our latest publication, just out today
@NatureComms, advancing our understanding of interstitial lung disease. Congrats to co-senior authors Drs. Jeremy Katzen and Kostas Alysandratos and their teams @Penn @CReM_Boston. Check it out here: www.nature.com/articles/s41...

30.09.2025 22:14 — 👍 7    🔁 4    💬 0    📌 0

Delighted to give a talk at the Vermont Lung Stem Cell Conference last week.

Also got to visit with @kottond.bsky.social, Finn Hawkins, Joe Kaserman, and Kostas Alysandratos - all legends of the lung regeneration field at the CReM Boston University
@crem-boston.bsky.social

#CureIPF

14.07.2025 17:30 — 👍 5    🔁 2    💬 1    📌 0

Co-development of mesoderm and endoderm enables organotypic vascularization in lung and gut organoids Recapitulating the concurrent development of germ layers through the co-differentiation of mesoderm and endoderm within a single spheroid enabled the generation of vascularized lung and intestinal org...

Congrats @MingxiaGu and all the teams collaborating on this latest advance in stem cell and lung organoid research, just out @CellCellPress! and thanks for including our iPSCs! www.cell.com/cell/fulltex...

30.06.2025 17:40 — 👍 2    🔁 1    💬 0    📌 0

Meenakshi Lakshminarayanan, MBA, Named Distinguished Staff of the Month for July | Chobanian & Avedisian School of Medicine

Congrats to our own Meenakshi Lakshminarayanan for being awarded Distinguished Staff of the Month. She is incredibly important to us! www.bumc.bu.edu/camed/news-e...

29.06.2025 15:44 — 👍 3    🔁 1    💬 0    📌 0

World's First Patient Treated with Personalized CRISPR Therapy In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children’s Hospital of Phila...

An amazing clinical triumph for regenerative medicine! A great example of how federal funding results in patient cures. Let’s keep these stories going, America! “World's First Patient Treated with Personalized CRISPR Therapy” #helpisontheway!

www.pennmedicine.org/news/news-re...

15.05.2025 19:07 — 👍 6    🔁 3    💬 0    📌 0

Pulmonologist Darrell Kotton Is BU’s Innovator of the Year Regenerative medicine researcher is recognized for his work in pioneering lung disease treatments with stem cell technology and accelerating scientific discovery with open-access resources

🎉 Pulmonologist Darrell Kotton is BU’s Innovator of the Year:
www.bu.edu/articles/202...

02.05.2025 21:21 — 👍 8    🔁 3    💬 0    📌 2

We are so proud of our director, @kottond.bsky.social, for being awarded BU’s Innovator of the Year!

02.05.2025 21:20 — 👍 3    🔁 2    💬 0    📌 0

…and there’s more!

Congrats to Dr. Todd Dowrey for receiving the Best Poster Award at the GMS Research Symposium! @todd-dowrey.bsky.social

10.04.2025 23:20 — 👍 2    🔁 0    💬 0    📌 0

Congrats to Dilnar Mahmut, one of our amazing trainees, for receiving the Outstanding Research Talk today at the GMS Research Symposium!

10.04.2025 23:20 — 👍 2    🔁 0    💬 0    📌 0

Congrats to our poster award winners, Kevin and Braden, for their excellent work at the BU CTSI symposium!

21.03.2025 01:43 — 👍 3    🔁 2    💬 0    📌 0

Today, we were treated to a great talk from Dr. Pulin Li of @whiteheadinstitute.bsky.social !

18.03.2025 22:31 — 👍 2    🔁 1    💬 0    📌 0

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation | Beam Therapeutics Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of

Gene editing is here for Alpha-1! @BeamTx clinical trial results announced: "the world’s first results in patients who have had a disease-causing mutation corrected at the genetic level." @AlphaFriend #helpisontheway #becausescience! Press release:
investors.beamtx.com/news-release...

10.03.2025 13:10 — 👍 3    🔁 2    💬 0    📌 0

At the CReM, we will always #standupforscience

08.03.2025 04:10 — 👍 4    🔁 1    💬 1    📌 1

No matter who you voted for the NIH is bipartisan and is here for you. Don’t stop now, America! So many medicines and treatments on the market today began with NIH funding. And we’re just getting warmed up! Keep it going!

Image below from: Bruce Levine, Ph.D. @BLLPHD

01.03.2025 00:19 — 👍 6    🔁 3    💬 0    📌 1

Last week, we celebrated yet another successful thesis defense! Congrats to Dr. Liz Flores, our BSL4 expert!

03.03.2025 20:27 — 👍 1    🔁 1    💬 0    📌 0